Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer

Cancer Letters

Volumn 359, Issue 2, 2015, Pages 178-186

  Dong, Dawen ^a   Gao, Wei ^a   Liu, Yujie ^a   Qi, Xian Rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Antiangiogenic; Co delivery of siRNA and doxorubicin; Cytotoxicity; Multifunctional nanocomplex; Synergistic treatment

Indexed keywords

DOXORUBICIN; MESSENGER RNA; POLYMER; SMALL INTERFERING RNA; VASCULOTROPIN; ANTINEOPLASTIC ANTIBIOTIC; NANOCONJUGATE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CAPILLARY DENSITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PH; SPHEROID CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENE SILENCING; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MULTICELLULAR SPHEROID; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR VOLUME; VASCULARIZATION;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL PROLIFERATION; DOXORUBICIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; NANOCONJUGATES; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923105792     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.011     Document Type: Article

References (75)

1. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med 1979, 91:710-717.
2. Vaishnaw A.K., Gollob J., Gamba-Vitalo C., Hutabarat R., Sah D., Meyers R., et al. A status report on RNAi therapeutics. Silence 2010, 1:14.
3. Dorsett Y., Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov 2004, 3:318-329.
4. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov 2007, 6:443-453.
5. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev 2009, 61:1203-1213.
6. Creixell M., Peppas A.N. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7:367-379.
7. Huang H.Y., Kuo W.T., Chou M.J., Huang Y.Y. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J. Biomed. Mater. Res. A 2011, 97:330-338.
8. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Jain R.K. Molecular regulation of vessel maturation. Nat. Med 2003, 9:685-693.
11. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res 1996, 2:1411-1416.
12. Liu T., Ye L., He Y., Chen X., Peng J., Zhang X., et al. Combination gene therapy using VEGFshRNA and fusion suicide gene yCDglyTK inhibits gastric carcinoma growth. Exp. Mol. Pathol 2011, 91:745-752.
13. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev 2004, 25:581-611.
14. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med 2003, 9:669-676.
15. Kirtane A.R., Kalscheuer S.M., Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv. Drug Deliv. Rev 2013, 65:1731-1747.
16. Vasudev N.S., Reynolds A.R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014, 17:471-494.
17. Salva E., Kabasakal L., Eren F., Cakalagaoglu F., Ozkan N., Akbuga J. Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma. Oligonucleotides 2010, 20:183-190.
18. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-3370.
19. Zakarija A., Soff G. Update on angiogenesis inhibitors. Curr. Opin. Oncol 2005, 17:578-583.
20. Quesada A.R., Munoz-Chapuli R., Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med. Res. Rev 2006, 26:483-530.
21. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol 2006, 3:24-40.
22. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med 2004, 350:2335-2342.
23. Fuchs C.S., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol 2007, 25:4779-4786.
24. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
25. Stylianopoulos S.T., Jain R.K. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18632-18637.
26. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
27. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
28. Le Serve A.W., Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. Br. Med. J. 1972, 1:597-601.
29. Kaye S.B. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?. J. Clin. Oncol 2007, 25:5150-5152.
30. Lindholm E.M., Kristian A., Nalwoga H., Kruger K., Nygard S., Akslen L.A., et al. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Mol. Oncol 2012, 6:418-427.
31. Li J., Wang Y., Zhu Y., Oupický D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J. Control. Release 2013, 172:589-600.
32. Zhu C., Jung S., Luo S., Meng F., Zhu X., Park T.G., et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMAPCL-PDMAEMA triblock copolymers. Biomaterials 2010, 31:2408-2416.
33. Malarvizhi G.L., Retnakumari A.P., Nair S., Koyakutty M. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine 2014, 10:1649-1659.
34. Yang Z., Li J., Wang Z., Dong D., Qi X. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 2014, 35:5226-5239.
35. Cao N., Cheng D., Zou S., Ai H., Gao J., Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011, 32:2222-2232.
36. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res 2008, 14:1310-1316.
37. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev 2011, 63:136-151.
38. Neri D., Supuran C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov 2011, 10:767-777.
39. Ohkuma S. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. USA 1978, 75:3327-3331.
40. Leamon C.P., Reddy J.A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev 2004, 56:1127-1141.
41. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1999, 52:3396-3401.
42. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines, physiologic and clinical implications. Cancer 1994, 73:2432-2443.
43. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev 2002, 54:675-693.
44. Dong D.W., Xiang B., Gao W., Yang Z.Z., Li J.Q., Qi X.R. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials 2013, 34:4849-4859.
45. Zhou L., Cheng R., Tao H., Ma S., Guo W., Meng F. Endosomal pH activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: Synthesis, drug release, and biodistribution in tumor-bearing mice. Biomacromolecules 2011, 12:1460-1467.
46. Dong D.W., Tong S.W., Qi X.R. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers. J. Biomed. Mater. Res. A 2013, 101:1336-1344.
47. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug. Chem 1996, 7:56-62.
48. 111In]DTPA-Folate for use as a tumor-targeted radiopharmaceutical. Bioconjug. Chem 1997, 8:673-679.
49. Kim S.H., Kim S.H., Jeong J.H., Cho K.C., Kim S.W., Park T.G. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J. Control. Release 2005, 108:121-131.
50. Gao W., Xiang B., Meng T.T., Liu F., Qi X.R. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 2013, 34:4137-4149.
51. Del Duca D., Werbowetski T., Del Maestro R.F. Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J. Neurooncol 2004, 67:295-303.
52. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv. Drug Deliv. Rev 2011, 63:161-169.
53. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 2011, 153:198-205.
54. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem. Rev 2009, 109:259-302.
55. Lu Z., Liu L., Qi X. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int. J. Nanomedicine 2011, 6:1661-1673.
56. Haycock J.W. 3D cell culture: a review of current approaches and techniques. Methods Mol. Biol 2011, 695:1-15.
57. Friedrich J., Ebner R., Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int. J. Radiat. Biol 2007, 83:849-871.
58. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen 2004, 9:273-285.
59. Mineo T.C., Ambrogi V., Baldi A., Rabitti C., Bollero P., Vincenzi B., et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J. Clin. Pathol 2004, 57:591-597.
60. Sun P., Gao J., Liu Y.L., Wei L.W., Wu L.P., Liu Z.Y. RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol. Cell. Biochem 2008, 308:161-168.
61. Raskopf E., Vogt A., Sauerbruch T., Schmitz V. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J. Hepatol 2008, 49:977-984.
62. Tanaka K., Kanazawa T., Ogawa T., Takashima Y., Fukuda T., Okada H. Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing. Int. J. Pharm 2010, 398:219-224.
63. Kanazawa T., Sugawara K., Tanaka K., Horiuchi S., Takashima Y., Okada H. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles. Eur. J. Pharm. Biopharm 2012, 81:470-477.
64. Etrych T., Mrkvan T., Ríhová B., Ulbrich K. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. J. Control. Release 2007, 122:31-38.
65. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., et al. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 2001, 74:295-302.
66. Tang N., Du G., Wang N., Liu C., Hang H., Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J. Natl. Cancer Inst 2007, 99:1004-1015.
67. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973, 33:302-314.
68. Speyer J.L., Green M.D., Kramer E., Rey M., Sanger J., Ward C., et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med 1988, 319:745-752.
69. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev 2004, 56:1067-1084.
70. Tran T., Shatnawi A., Zheng X., Kelley K.M.M., Ratnam M. Enhancement of folate receptor α expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Res 2005, 65:4431-4441.
71. Pan X.Q., Zheng X., Shi G., Wang H., Ratnam M., Lee R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor h-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002, 100:594-602.
72. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., et al. Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999, 85:348-357.
73. Shen F., Ross J.F., Wang X., Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type β in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 1994, 33:1209-1215.
74. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type γ is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry 1995, 34:5660-5665.
75. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur. J. Cancer 1994, 30A:363-369.